drugset / Trial / NCT03633357

Imaging 5HT7 Antagonist Effects in Bipolar Disorder

NCT03633357

Unknown 68 enrolled King's College London
RandomizedCrossoverDouble-blindBasic science

Summary

The main aim of this research is to examine the potential of 5HT7 antagonists for the treatment of cognitive impairment in bipolar disorder by determining the effect of the 5HT7 antagonist JNJ-18038683 on cognitive and emotional processing related brain activity in cognitively impaired people with bipolar disorder and healthy participants using functional MRI (fMRI). This study is designed to contribute to the rational validation of 5HT7 antagonists as a treatment for cognitive impairment in bipolar disorder and to support the development of clinical trials and further drug development in this area. The study will also examine the effect of 5HT7 antagonism on brain function in healthy participants as this has never been investigated before, and to use as a comparator to determine whether 5HT7 antagonism effects disease specific impairments in task related brain activity and cerebral blood flow.

Timeline

Start
2018-08-16
Primary completion
2022-06
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-18038683 Small molecule 20 mg Oral

Indications